Selank for Depression
Research, mechanism, dosing, and effectiveness of Selank for depression.
Quick Answer
Selank may help with mild depressive symptoms through neurotransmitter modulation.
Evidence Level
Human Trials
Typical Dose
200-400 mcg daily
Results Timeline
Mood improvements within 2-4 weeks
FDA Status
Research Only
How Selank Works for Depression
Serotonin and GABA effects support mood stability.
About Depression
Support for mood and depressive symptoms.
Research Evidence
Russian clinical trials demonstrate anxiolytic effects comparable to benzodiazepines without sedation or addiction potential. Studies show improved cognitive function under stress, enhanced memory, and stabilization of mood. Note: Selank was removed from FDA Category 2 in September 2024 when nominators withdrew the substance - now scheduled for PCAC review.
Dosing for Depression
Recommended Dose
200-400 mcg daily
Frequency
2-3x daily, intranasal
Administration
Intranasal spray (most common), subcutaneous injection
Duration
14-21 days typical
Note: Anxiolytic nootropic. Used intranasally. Effects build over days/weeks. Often stacked with Semax.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Generally well-tolerated
- •Nasal irritation (spray)
- •Headache
- •Nausea
- •Fatigue
- •Non-sedative and non-addictive
Frequently Asked Questions
Does Selank help with depression?
Selank may help with mild depressive symptoms through neurotransmitter modulation.
How does Selank work for depression?
Serotonin and GABA effects support mood stability....
What dose of Selank should I use for depression?
200-400 mcg daily
How long until I see results?
Mood improvements within 2-4 weeks
Other Peptides for Depression
These peptides are also researched for depression.
Semax
Clinical TrialsA synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
Cerebrolysin
Clinical TrialsA mixture of low-molecular-weight neuropeptides derived from pig brain. Approved in many countries for stroke, traumatic brain injury, and dementia.
Dihexa
PreclinicalA potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
GB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.